Certified by Founder Lodge
Janus Henderson Investors
United Kingdom - London
INVESTOR
1 Disclosed Funding Rounds $200,000,000
142 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Janus Henderson Investors exists to help clients achieve their long-term financial goals.
Formed in 2017 from the merger between Janus Capital Group and Henderson Global Investors, we are
| Company | Date | Round | Raised |
|---|---|---|---|
 Asher Biotherapeutics |
April, 17 ,2024 | Series C | $55,000,000 |
 Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
 CARGO Therapeutics |
March, 06 ,2023 | Series A | $200,000,000 |
 Parse Biosciences |
February, 15 ,2022 | Series B | $41,500,000 |
 HeartFlow, Inc |
April, 07 ,2023 | Series F | $215,000,000 |
| CARGO Therapeutics |
March, 06 ,2023 | Series A | $200,000,000 |
| Asher Biotherapeutics |
April, 17 ,2024 | Series C | $55,000,000 |
 Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
 Bicara Therapeutics |
March, 07 ,2023 | Series B | $108,000,000 |
| Asher Biotherapeutics |
April, 17 ,2024 | Series C | $55,000,000 |
| HeartFlow, Inc |
April, 07 ,2023 | Series F | $215,000,000 |
| CARGO Therapeutics |
March, 06 ,2023 | Series A | $200,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| HeartFlow, Inc |
April, 07 ,2023 | Series F | $215,000,000 |
| Parse Biosciences |
February, 15 ,2022 | Series B | $41,500,000 |
| Asher Biotherapeutics |
April, 17 ,2024 | Series C | $55,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Bicara Therapeutics |
March, 07 ,2023 | Series B | $108,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| HeartFlow, Inc |
April, 07 ,2023 | Series F | $215,000,000 |
| Asher Biotherapeutics |
April, 17 ,2024 | Series C | $55,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| CARGO Therapeutics |
March, 06 ,2023 | Series A | $200,000,000 |
| Parse Biosciences |
February, 15 ,2022 | Series B | $41,500,000 |
| Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Asher Biotherapeutics |
April, 17 ,2024 | Series C | $55,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Bicara Therapeutics |
March, 07 ,2023 | Series B | $108,000,000 |
| Asher Biotherapeutics |
April, 17 ,2024 | Series C | $55,000,000 |
| HeartFlow, Inc |
April, 07 ,2023 | Series F | $215,000,000 |
| CARGO Therapeutics |
March, 06 ,2023 | Series A | $200,000,000 |
| Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
| Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
| Bicara Therapeutics |
March, 07 ,2023 | Series B | $108,000,000 |
| Asher Biotherapeutics |
April, 17 ,2024 | Series C | $55,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Bicara Therapeutics |
March, 07 ,2023 | Series B | $108,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| HeartFlow, Inc |
April, 07 ,2023 | Series F | $215,000,000 |
| Parse Biosciences |
February, 15 ,2022 | Series B | $41,500,000 |
| Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
| Bicara Therapeutics |
March, 07 ,2023 | Series B | $108,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
| Parse Biosciences |
February, 15 ,2022 | Series B | $41,500,000 |
| Asher Biotherapeutics |
April, 17 ,2024 | Series C | $55,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| HeartFlow, Inc |
April, 07 ,2023 | Series F | $215,000,000 |
| Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
| Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
| Asher Biotherapeutics |
April, 17 ,2024 | Series C | $55,000,000 |
| Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
| HeartFlow, Inc |
April, 07 ,2023 | Series F | $215,000,000 |
| Bicara Therapeutics |
March, 07 ,2023 | Series B | $108,000,000 |
| Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
| Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
| Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
 Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Bicara Therapeutics |
March, 07 ,2023 | Series B | $108,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
| Parse Biosciences |
February, 15 ,2022 | Series B | $41,500,000 |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Asher Biotherapeutics |
April, 17 ,2024 | Series C | $55,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Parse Biosciences |
February, 15 ,2022 | Series B | $41,500,000 |
| Parse Biosciences |
February, 15 ,2022 | Series B | $41,500,000 |
| HeartFlow, Inc |
April, 07 ,2023 | Series F | $215,000,000 |
| Asher Biotherapeutics |
April, 17 ,2024 | Series C | $55,000,000 |
| Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
| Parse Biosciences |
February, 15 ,2022 | Series B | $41,500,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| HeartFlow, Inc |
April, 07 ,2023 | Series F | $215,000,000 |
| HeartFlow, Inc |
April, 07 ,2023 | Series F | $215,000,000 |
| Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
| HeartFlow, Inc |
April, 07 ,2023 | Series F | $215,000,000 |
| Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
| Asher Biotherapeutics |
April, 17 ,2024 | Series C | $55,000,000 |
| Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
| Parse Biosciences |
February, 15 ,2022 | Series B | $41,500,000 |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Asher Biotherapeutics |
April, 17 ,2024 | Series C | $55,000,000 |
| Asher Biotherapeutics |
April, 17 ,2024 | Series C | $55,000,000 |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Parse Biosciences |
February, 15 ,2022 | Series B | $41,500,000 |
| HeartFlow, Inc |
April, 07 ,2023 | Series F | $215,000,000 |
| Asher Biotherapeutics |
April, 17 ,2024 | Series C | $55,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| HeartFlow, Inc |
April, 07 ,2023 | Series F | $215,000,000 |
 Angitia Biopharmaceuticals |
December, 12 ,2024 | Series C | $120,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
| Angitia Biopharmaceuticals |
December, 12 ,2024 | Series C | $120,000,000 |
| Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
 Curevo Vaccine |
March, 19 ,2025 | Series B | $110,000,000 |
| Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
| Asher Biotherapeutics |
April, 17 ,2024 | Series C | $55,000,000 |
| Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Curevo Vaccine |
March, 19 ,2025 | Series B | $110,000,000 |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Asher Biotherapeutics |
April, 17 ,2024 | Series C | $55,000,000 |
 Galvanize |
September, 04 ,2025 | Series C | $100,000,000 |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Angitia Biopharmaceuticals |
December, 12 ,2024 | Series C | $120,000,000 |
| Galvanize |
September, 04 ,2025 | Series C | $100,000,000 |
| Angitia Biopharmaceuticals |
December, 12 ,2024 | Series C | $120,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Curevo Vaccine |
March, 19 ,2025 | Series B | $110,000,000 |
| Angitia Biopharmaceuticals |
December, 12 ,2024 | Series C | $120,000,000 |
| Angitia Biopharmaceuticals |
December, 12 ,2024 | Series C | $120,000,000 |
| Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
| Curevo Vaccine |
March, 19 ,2025 | Series B | $110,000,000 |
| Galvanize |
September, 04 ,2025 | Series C | $100,000,000 |
| Metsera |
November, 14 ,2024 | Series B | $215,000,000 |
| Curevo Vaccine |
March, 19 ,2025 | Series B | $110,000,000 |
| Galvanize |
September, 04 ,2025 | Series C | $100,000,000 |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Galvanize |
September, 04 ,2025 | Series C | $100,000,000 |
| Angitia Biopharmaceuticals |
December, 12 ,2024 | Series C | $120,000,000 |
| Curevo Vaccine |
March, 19 ,2025 | Series B | $110,000,000 |
| Curevo Vaccine |
March, 19 ,2025 | Series B | $110,000,000 |
 Artios |
November, 18 ,2025 | Series D | $115,000,000 |
 BlossomHill Therapeutics, Inc. |
December, 17 ,2025 | Series B | $84,000,000 |
 Diagonal Therapeutics |
January, 13 ,2026 | Series B | $125,000,000 |
 Think Bioscience |
January, 21 ,2026 | Series A | $55,000,000 |
Founderpath
Truework
Finix
Farther
TeamApt Inc.
Datatruck | $12,000,000 | (Jan 29, 2026)
Scholé AI | $3,000,000 | (Jan 29, 2026)
Tenbin Labs | $7,000,000 | (Jan 29, 2026)
Adaptive6 | $28,000,000 | (Jan 29, 2026)
Vention | $110,000,000 | (Jan 29, 2026)
